Delivering Innovation to the EyeTM
Focused on developing and commercializing innovative ophthalmic products and technologies for serious ophthalmic diseases
- EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU® Within One of the Largest Integrated Delivery Systems in the U.S.
- EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility
- EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development
- EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress
- EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule